Eli Lilly reported strong first-quarter earnings driven by overseas sales of Mounjaro (tirzepatide), beating Wall Street forecasts and raising full-year guidance. The company now controls 60% of the U.S. GLP-1 market and is focusing on Foundayo, its newly approved pill version, with 80% of early prescriptions going to patients trying the drug class for the first time.

• •Q1 revenue jumped 56% to $19.8 billion, beating estimates by over $2 billion
• •Mounjaro/Zepbound sales more than doubled to $8.7 billion in the quarter
• •Lilly holds 60% of US GLP-1 market vs Novo's 39.4%